semaglutide long-term safety A new clinical trial supported by the National Institutes of Health (NIH) found that a medication commonly used for weight loss, such as semaglutide, may also help reduce heavy drinking in individuals Study raises red flags over

Novo Nordisks Peter Johannsen, MD, highlighted the biological signals observed and acknowledged the clinical limitations: subgroup analyses did not reveal meaningful benefit, and any potential responder group would be very small

Plus, a new genetic test predicts how well Ozempic will work on patients

It must be prescribed carefully, by only trained physicians, endos and also cardiologists.

Discuss GLP-1 and GIP treatment options, including Tirzepatide, Semaglutide, Mounjaro, Zepbound, Wegovy, and Ozempic for eligible patients

It highlights emerging evidence, safety considerations, and equity challenges that position GLP-1 RAs as a promising public health strategy for this high-risk population.